Sign In
Buy GLP
$48.63
+0.410 (+0.85%)
At Close: Jul 28, 2026
•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, includin
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?
10:36am, Friday, 05'th Jun 2026
LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.
New PatentVest Pulse Report Maps the Emerging Muscle-Preservation Category Expanding the GLP-1 Opportunity
01:05pm, Thursday, 04'th Jun 2026
• Analysis of 20 muscle-preservation programs highlights a rapidly emerging category designed to enhance long-term obesity treatment outcomes
Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies
12:17pm, Thursday, 04'th Jun 2026
WW International (NASDAQ:WW) on Thursday said its Weight Watchers platform is now available through Eli Lilly Co.'s (NYSE:LLY) LillyDirect digital health care platform, expanding access to branded GLP
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success
09:27am, Thursday, 04'th Jun 2026
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are seeing massive demand. Like all drugs, Mounjaro and Zepbound have time-limited patent protections.
Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure
Should Value Investors Buy Global Partners (GLP) Stock?
10:40am, Wednesday, 03'rd Jun 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Wegovy pill maintains GLP-1 lead over Lilly rival, but weekly growth slows
08:59am, Monday, 01'st Jun 2026
Novo Nordisk's (NYSE:NVO) oral GLP-1 weight-loss drug Wegovy pill continues to outsell Eli Lilly's recently launched competing tablet, but weekly prescription growth is slowing as the market absorbs a
Lilly's Mounjaro tops other GLP-1s for some type 2 diabetes patients
07:03am, Friday, 29'th May 2026
We also report on two studies with findings that could bring eventual relief for patients still struggling with long COVID symptoms.
Lilly's GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans
03:08pm, Thursday, 28'th May 2026
That means millions more Americans may get access to Lilly's new GLP-1 pill Foundayo or the GLP-1 injection Zepbound.
Novo Nordisk faces complex GLP-1 landscape as oral launch patterns diverge from injectables
09:07am, Thursday, 28'th May 2026
Novo Nordisk's (NYSE:NVO) investor relations team presented at Deutsche Bank's European Champions Conference, with the broker maintaining its hold rating and DKK290 target price on the Danish pharma g
Wall Street Underestimates Novo Nordisk's GLP-1 Comeback
08:59am, Thursday, 28'th May 2026
Despite Wall Street skepticism, Novo Nordisk A/S is starting to catch up with Eli Lilly, the market leader in the GLP-1s market. This skepticism mainly reflects declining demand for Ozempic, as well a
CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options
06:45am, Thursday, 28'th May 2026
Expanded GLP-1 options for members create a path to sustainable coverage of these important medications WOONSOCKET, R.I., May 28, 2026 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced updates t
Signos grows foothold in weight-loss wave fueled by GLP-1s with its AI health data tracking
09:07am, Wednesday, 27'th May 2026
Health tech startup Signos announced a $20 million funding round and expanded its partnership with medical device giant Dexcom. Signos makes an AI-powered glucose monitoring system designed to help wi
Novo Nordisk faces new GLP-1 rival as Eli Lilly's triple agonist sets weight-loss record
11:11am, Friday, 22'nd May 2026
Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a pivotal trial showed patients losing 28% of t
